Hematology Diagnostics Market Synopsis

Market Research Future (MRFR) speculates that the global hematology diagnostics market is predicted to demonstrate a robust CAGR during the forecast period (2018–2023) owing to the augmenting prevalence of blood disorders. Hematology is referred to as the branch of science which deals with the prognosis, cause, treatment, and prevention of blood disorders. Hematology diagnosis comprises the calculation of WBC, RBC, and platelets. It consists of the problems associated with RBC, WBC, lymph, bone marrow, and platelets. It comprises IVD technologies like flow cytometry, blood analysis, molecular diagnostics, immunodiagnostics, histology, hemostasis, and cytology.

Hematology Diagnostics Market Potential and Pitfalls

The augmenting prevalence of blood disorders coupled with technological advancements is considered to contribute to the hematology diagnostics market growth. Factors influencing the hematology diagnostics market are the rising incidences of genetic diseases, high adoption of hematology analyzers, increasing blood transfusions and donations, and rising hematological testing. As per the CDC and Prevention, around 70,000 to 100,000 of the Americans suffered from sickle cell disease in 2017, which is considered as a genetic blood disorder.

Automation is considered as one of the major areas of focus for hematology labs. Laboratories are extensively adopting automation for analytical, post-analytical, and pre-analytical steps in order to improve efficiency and also standardize the process. Processes such as processing, automation sample collection, test ordering, and test identification minimize the administrative errors besides facilitating reliable test results. Such factors are anticipated to contribute to the market growth to a large extent. Moreover, the increasing adoption of point-of-care (POC) hematology tests is presumed to influence the markeat growth as these tests are user-friendly and reduces the need for user-training.

On the contrary, poor healthcare insurance coverage for diagnosis, the high cost of diagnosis, and lack of awareness are some of the major concerns anticipated to slow down the market growth throughout the appraisal period.

Global Hematology Diagnostics Market: Segmental Analysis

The global hematology diagnostics market has been segmented on the basis of tests, product type, and end-user.

By mode of product type, the global hematology diagnostics market has been segmented into flow cytometers, hematology analyzers, and consumables. Among these, the hematology consumables segment is predicted to lead the global market owing to the increasing awareness of blood disorders among the patients and the healthcare professionals. Moreover, with the rising test volume due to the increasing awareness and early detection, the segment is considered to flourish.

By mode of tests, the global hematology diagnostics market has been segmented into hemoglobinopathy, anemia, hematology pathophysiology, leukemia/lymphoma phenotyping, complete blood count (CBC), and others.

By mode of end-users, the global hematology diagnostics market has been segmented into ambulatory surgical centers, hospitals and clinics, academic institutes, diagnostic laboratories, and others. Among these, the hospital's segment is considered to dominate the global market. Diagnostic laboratories are predicted to expand at a rapid pace owing to the rising number of diagnostic centers coupled with the availability of advanced instruments.

Hematology Diagnostics Market Regional Insights

Geographically, the hematology diagnostics market span across regions namely, Europe, America, Asia-Pacific, and the Middle East and Africa.

Among all the regions, the North American region is predicted to dominate the global hematology diagnostics market and is likely to retain its dominance in the coming years. The growth is credited to the increasing prevalence of blood diseases in this region. As per Statista, 33% of all the Americans were diagnosed with hemophilia A in 2016. Factors contributing to the market growth are the presence of market giants like Bio-Rad Laboratories, Abbott Laboratories Danaher, and others coupled with the technological advancements and rising healthcare expenditure in this region.

The European region is predicted to occupy the second largest position in the global market owing to the rising hematology research in this region. For instance, the 16^th World Hematology Congress will be conducted in London, in March 2019 in order to discuss the blood disorders, treatment, and diagnosis of hematology, hematologic disorders, hematologic oncology, and immunohematology.

The Asia Pacific region is anticipated to expand at the fastest rate due to the increasing prevalence of genetic diseases and blood disorders in this region.

Browse Full Report with TOC at: https://www.marketresearchfuture.com/reports/hematology-diagnostics-market-6262

Hematology Diagnostics Industry Updates

February 14, 2019: The ERBA Group, a leading global In-vitro diagnostic company, at their recently concluded MEDLAB expo, launched their latest hematology analyzers H 560 and H 360. They have been designed to improve the efficiency of the lab. With the emergence of these systems, better healthcare outcomes are penetrating the global market.

Hematology Diagnostics Market Competitive Dashboard

The prominent players operating the global hematology diagnostics market are BioSystems (Spain), Ortho Clinical Diagnostics (US), Abbott Laboratories (US), EKF Diagnostics (UK), Diatron (Hungary), Sysmex (Japan), Roche (Switzerland), Siemens (Germany), Boule Diagnostics (Sweden), Danaher (US), Mindray (China), Bio-Rad Laboratories (US), Drew Scientific (US), Nihon Kohden (Japan), HORIBA (Japan), and others.